STAAR Surgical Generates Cash From Operations During Seco...(s of public sale of equity secu...),Health

Date:8/3/2009

s of public sale of equity securities 8,548 - ----- - Net cash provided by financing activities 8,619 1,481 ----- ----- Effect of exchange rate changes on cash and cash equivalents (184) 404 ---- --- Decrease in cash and cash equivalents 762 (2,044) Cash and cash equivalents, at beginning of the period 4,992 10,895 ----- ------ Cash and cash equivalents, at end of the period $5,754 $8,851 ====== ====== STAAR Surgical Company GAAP Reconciliation Tables (in 000's) Unaudited Three Months Ended Six Months Ended ------------------ ---------------- July 3, June 27, July 3, June 27, 2009 2008 2009 2008 ---- ---- ---- ---- Adjusted EBITDA Net loss (1,088) (2,545) (2,750) (11,485) Income taxes 280 396 716 654 Interest income (5) (63) (8) (91) Interest expense 399 222 632 423 Depreciation 581 538 1,156 1,340 Amortization 193 176 390 418 ---
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine news :

1. STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York
2. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
3. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
4. STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And Conference Call
5. Richard A. Meier Appointed to STAAR Surgical Board of Directors
6. STAAR Surgical Completes Common Stock Offering
7. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
8. STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call
9. STAAR Surgical Reports 14% Fourth Quarter Revenue Growth
10. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
11. STAAR Surgical Reports 33% Third Quarter Revenue Growth